Canadian Cancer Trials Group Bulletins

Trial Management Group

Trial Closed to Accrual

Canadian Cancer Trials Group CE.5 (EORTC 22033-26033) - Primary Chemotherapy with Temozolomide vs. Radiotherapy in Patients with Low Grade Gliomas After Stratification for Genetic 1p Loss: A Phase III Study - was closed to accrual on April 11.

As you will recall, the trial was closed to new registrations in March, 2010. The final primary analysis results for this trial have now been presented at the EORTC Brain Tumour Group meeting, and these results will be presented at ASCO 2013. No further accrual is required for the trial.

Thanks to all participating centres, staff and patients for their participation in this trial.